Clinical Trial Update: Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) [Phase 3]

View source ↗

Summary

Phase 3 trial of sacituzumab govitecan in refractory/relapsed metastatic triple-negative breast cancer has completed; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Sacituzumab Govitecan (sacituzumab govitecan)

Snippet

Sponsor: Gilead Sciences | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2021-04-30